Search company, investor...
CureVac company logo

CureVac

curevac.com

Founded Year

2000

Stage

IPO | IPO

Total Raised

$1.281B

Date of IPO

8/14/2020

Market Cap

1.43B

Stock Price

7.47

About CureVac

CureVac, a German clinical stage biopharmaceutical company, serves the field of mRNA-based technology platforms for medical purposes, in which unmodified mRNA is specifically optimized and formulated. CureVac has been developing mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases – both under the brand RNActive. Moreover, CureVac's technology RNArt is designed as a molecular therapy to trigger the body's own production of therapeutic proteins without stimulating the immune system.

Headquarters Location

Friedrich-Miescher-Str. 15

Tubingen, 72076,

Germany

+49 7071 9883 - 0

Missing: CureVac's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: CureVac's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing CureVac

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned CureVac in 5 CB Insights research briefs, most recently on Oct 13, 2022.

Expert Collections containing CureVac

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CureVac is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

CureVac Patents

CureVac has filed 1 patent.

The 3 most popular patent topics include:

  • Molecular biology
  • RNA
  • Vaccines
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/5/2021

11/8/2022

Molecular biology, Biotechnology, RNA, DNA, Genetics

Grant

Application Date

12/5/2021

Grant Date

11/8/2022

Title

Related Topics

Molecular biology, Biotechnology, RNA, DNA, Genetics

Status

Grant

Latest CureVac News

Wall Street Analysts Believe CureVac N.V. (CVAC) Could Rally 139%: Here's is How to Trade

Nov 22, 2022

Nasdaq By Zacks CureVac N.V. (CVAC) closed the last trading session at $7.95, gaining 6.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $19 indicates a 139% upside potential. The mean estimate comprises three short-term price targets with a standard deviation of $13.08. While the lowest estimate of $10 indicates a 25.8% increase from the current price level, the most optimistic analyst expects the stock to surge 327.7% to reach $34. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. AD AD While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice.

CureVac Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

CureVac Rank

CureVac Frequently Asked Questions (FAQ)

  • When was CureVac founded?

    CureVac was founded in 2000.

  • Where is CureVac's headquarters?

    CureVac's headquarters is located at Friedrich-Miescher-Str. 15, Tubingen.

  • What is CureVac's latest funding round?

    CureVac's latest funding round is IPO.

  • How much did CureVac raise?

    CureVac raised a total of $1.281B.

  • Who are the investors of CureVac?

    Investors of CureVac include Qatar Investment Authority, GSK, European Investment Bank, KfW, European Commission and 14 more.

  • Who are CureVac's competitors?

    Competitors of CureVac include Ethris.

Compare CureVac to Competitors

Recode Therapeutics Logo
Recode Therapeutics

ReCode Therapeutics is a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. The SORT LNP platform is the foundation for ReCode’s pipeline of disease-modifying mRNA and gene correction therapeutics. ReCode’s lead programs are focused on primary ciliary dyskinesia and cystic fibrosis. ReCode is leveraging its SORT LNP platform and nucleic acid technologies to expand its pipeline with therapeutics that use mRNA-mediated replacement and gene correction in target organs with precision targeting of disease-relevant cells. Recode Therapeutics was founded in 2015 and is based in Menlo Park, California.

Ethris Logo
Ethris

Ethris is paving a new path from genes to therapeutic proteins using its messenger RNA technology platform, which enables the discovery, design and development of transcript therapies that restore missing functions in patients' cells and tissues. Ethris is advancing transcript therapies to transform the treatment of disease.

BioNTech Logo
BioNTech

BioNTech is developing personalized immunotherapies to help the treatment of people with cancer and other debilitating diseases.

Moderna Therapeutics Logo
Moderna Therapeutics

Moderna Therapeutics (NASDAQ:MRNA) is a Cambridge, Massachusetts-based biotechnology company that is focused on drug discovery and drug development based on messenger RNA. The company creates synthetic mRNA that can be injected into patients to help them create their own therapies.

A
Arcturus Therapeutics

Arcturus Therapeutics (NASDAQ: ARCT) focuseS on the discovery and development of therapeutic modalities to pursue RNA interference (RNAi) solutions for rare diseases for which there is no adequate treatment.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.